Pain Therapeutics’ Remoxy Is More Abuse-Resistant Than Other Oxycodone Formulations, FDA Panel Suggests
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval may depend on FDA’s confidence that the firm’s proposed REMS can adequately monitor for abuse – a subject of apparent debate within FDA.